Enanta Pharmaceuticals Inc (NAS:ENTA)
$ 12.13 -0.93 (-7.12%) Market Cap: 256.91 Mil Enterprise Value: 23.29 Mil PE Ratio: 0 PB Ratio: 1.55 GF Score: 70/100

Enanta Pharmaceuticals Inc at JMP Securities Life Sciences Conference Transcript

Jun 16, 2022 / 01:30PM GMT
Release Date Price: $39.8 (-0.50%)
Unidentified Participant

Thank you for joining us again for the JMP Securities Life Science Conference. Next company we have is Enanta Pharmaceuticals, and we have Jay Luly, the CEO of Enanta. So thanks for joining us, Jay.

Questions & Answers

Unidentified Participant

I'm going to jump right in on the programs. You guys are focused on small molecules, antivirals. So let's start talking about COVID, your lead program there, EDP-235. We're expecting Phase 1, first-in-human Phase 1 results next month. Maybe just walk us through what we can expect there. We kind of expected the results this month, and they've moved to next month. So maybe you can describe why their timeline shifted a little bit.

Jay Luly
Enanta Pharmaceuticals, Inc. - President, CEO & Director

Sure. So thanks for the opportunity to chat today. Before I begin, I want to remind you I'll be making some forward-looking statements, and for a summary of the risks associated with these statements, please see our filings on sec.gov and on our website.

Yes.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot